The Targeted Sequencing Market size was estimated at USD 7.60 billion in 2025 and expected to reach USD 8.61 billion in 2026, at a CAGR of 13.51% to reach USD 18.46 billion by 2032.

Targeted sequencing is becoming a core approach in precision medicine, translational research, infectious disease surveillance, reproductive health, and agricultural genomics because it enables focused analysis of selected genes, genomic regions, or biomarker panels with greater depth than broad whole-genome workflows. By concentrating sequencing reads on clinically or scientifically relevant targets, laboratories can improve sensitivity for low-frequency variants, reduce data interpretation complexity, and accelerate turnaround for applications such as oncology variant profiling, inherited disease testing, pharmacogenomics, antimicrobial resistance detection, and companion diagnostic development. The field is supported by advances in next-generation sequencing, hybrid capture and amplicon enrichment, liquid biopsy workflows, automation, bioinformatics pipelines, and increasingly standardized variant interpretation frameworks. Demand is also shaped by healthcare systems moving from generalized treatment pathways toward molecularly informed decisions, while research institutions and public health agencies use targeted sequencing to monitor pathogens, track mutations, and validate biological mechanisms. As regulatory expectations, data privacy requirements, reimbursement pathways, and clinical evidence standards mature, targeted sequencing is shifting from a specialized research tool into an operationally critical technology across diagnostics, population health, and biopharmaceutical development.

The targeted sequencing landscape is being reshaped by a convergence of clinical adoption, workflow automation, multi-omics integration, and stronger quality requirements. Oncology remains a major driver as tumor profiling, hereditary cancer panels, minimal residual disease research, and liquid biopsy applications require high-depth detection of clinically relevant variants. In parallel, rare disease diagnostics and carrier screening are expanding the use of focused panels where curated gene content can improve interpretability and support faster clinical reporting. Infectious disease and public health programs are also adopting targeted sequencing for pathogen characterization, outbreak investigation, and antimicrobial resistance surveillance, especially when rapid mutation tracking is required. Operationally, laboratories are moving toward end-to-end sample-to-report workflows that combine automated library preparation, optimized enrichment chemistries, standardized controls, cloud-enabled analysis, and knowledgebase-supported interpretation. At the same time, the industry is facing pressure to demonstrate analytical validity, clinical validity, data security, interoperability, and reproducibility across sites. These shifts are encouraging the development of flexible panels, decentralized testing models, and informatics platforms that can adapt to changing biomarker guidelines without compromising compliance or reporting consistency.

Artificial intelligence is creating a cumulative impact across the targeted sequencing value chain by improving assay design, variant calling, quality control, interpretation, and clinical decision support. Machine learning models help optimize panel content by analyzing literature, disease associations, variant databases, and clinical guideline updates, enabling more precise selection of genes and regions of interest. In sequencing analysis, AI-enabled algorithms can support error suppression, noise modeling, low-frequency variant detection, copy number analysis, structural variant interpretation, and detection of complex mutational signatures, particularly in oncology and liquid biopsy applications where signal-to-noise challenges are significant. Natural language processing is increasingly relevant for extracting evidence from scientific publications, clinical trial records, and curated knowledge sources to assist variant classification and reporting. AI also supports laboratory operations through anomaly detection, batch quality monitoring, sample tracking, and predictive maintenance for high-throughput environments. However, responsible deployment requires transparent validation, bias assessment, auditability, cybersecurity safeguards, and alignment with clinical laboratory standards. The most sustainable impact of AI in targeted sequencing will come from augmenting expert molecular interpretation rather than replacing it, particularly where clinical context, ancestry diversity, and evolving evidence must be carefully evaluated.

In Asia-Pacific, targeted sequencing adoption is supported by expanding genomics infrastructure, growing cancer and rare disease programs, national precision medicine initiatives, and increasing use of molecular diagnostics in China, Japan, India, South Korea, Australia, and ASEAN economies. The region’s scale and genetic diversity create strong opportunities for population-specific variant interpretation, although uneven access to advanced diagnostics and bioinformatics expertise remains a practical barrier. North America demonstrates mature adoption across oncology diagnostics, academic medical centers, clinical laboratories, public health genomics, and biopharmaceutical research, with the United States and Canada emphasizing regulatory-grade validation, reimbursement evidence, interoperability, and data privacy. Latin America is advancing through oncology-focused molecular testing, infectious disease surveillance, and academic collaborations, with Brazil and Mexico serving as important centers for expanding clinical genomics access while cost sensitivity and infrastructure variability influence implementation. Europe benefits from coordinated healthcare systems, cross-border research frameworks, biobanking networks, and strong regulatory attention to in vitro diagnostics, data protection, and clinical evidence, supporting targeted sequencing in oncology, inherited disease, and pharmacogenomics. The Middle East is investing in genomic medicine, national population genomics, and advanced hospital infrastructure, particularly across Gulf economies, where targeted sequencing supports hereditary disease screening and precision oncology. Africa’s adoption is emerging through infectious disease genomics, antimicrobial resistance monitoring, oncology capacity building, and academic-public health partnerships, with long-term progress dependent on sustainable sequencing infrastructure, workforce training, sample logistics, and locally relevant genomic reference data.

ASEAN economies are strengthening targeted sequencing capabilities through hospital modernization, infectious disease surveillance, cancer diagnostics, and regional academic collaborations, while differences in reimbursement, laboratory accreditation, and bioinformatics capacity shape adoption patterns across member states. The GCC is increasingly focused on precision medicine, hereditary disorder screening, premarital and newborn testing, and oncology genomics, supported by national health transformation programs and investment in advanced diagnostic infrastructure. The European Union provides a highly structured environment for targeted sequencing through harmonized regulatory expectations, data protection rules, cross-border research programs, and coordinated cancer and rare disease initiatives, although implementation still varies across national health systems. BRICS countries collectively represent a major growth engine for clinical and research sequencing due to large patient populations, expanding biotechnology capacity, public health genomics needs, and rising domestic investment in molecular diagnostics; however, affordability, standardization, and local reference database development remain central issues. G7 countries show comparatively mature targeted sequencing use in clinical oncology, rare disease diagnosis, pharmacogenomics research, and regulatory science, with emphasis on evidence generation, quality management, and integration into care pathways. NATO countries overlap significantly with advanced genomics adopters in North America and Europe, where secure data infrastructure, biosecurity, pathogen surveillance, and resilient healthcare systems increasingly connect targeted sequencing with preparedness and public health intelligence.

The United States leads in broad clinical and research use of targeted sequencing, driven by oncology biomarker testing, companion diagnostics, rare disease evaluation, liquid biopsy development, and a large ecosystem of accredited laboratories and academic medical centers. Canada emphasizes precision oncology, provincial genomic medicine programs, public health sequencing, and equitable access across a geographically dispersed healthcare system. Mexico is expanding targeted sequencing through cancer diagnostics, inherited disease testing, and collaborations with research institutions, while infrastructure and affordability influence broader access. Brazil has one of Latin America’s most active genomics environments, with growing application in oncology, infectious disease, and population research, supported by major academic and hospital networks. The United Kingdom is recognized for integrating genomics into national healthcare pathways, rare disease programs, cancer testing, and clinical research infrastructure. Germany applies targeted sequencing across oncology, molecular pathology, inherited disorders, and translational medicine, supported by strong laboratory quality systems and biomedical research capacity. France is advancing genomic medicine through national plans, cancer molecular profiling, and rare disease networks, while Italy and Spain continue expanding targeted sequencing in oncology, hereditary disease, and academic clinical research across regional health systems. Russia maintains capabilities in molecular diagnostics and biomedical research, with adoption influenced by domestic healthcare priorities and infrastructure distribution. China is a major force in targeted sequencing due to large-scale genomics capacity, oncology testing demand, reproductive health applications, infectious disease surveillance, and rapid technology deployment. India is advancing targeted sequencing in oncology, rare diseases, reproductive genetics, pharmacogenomics, and infectious disease research, with rising emphasis on cost-effective panels and population-specific variant data. Japan combines advanced clinical laboratory standards with strong oncology, pharmacogenomics, and inherited disease applications, while South Korea demonstrates high adoption readiness through digital healthcare infrastructure, cancer genomics, and biomedical innovation. Australia applies targeted sequencing in cancer care, rare disease diagnosis, public health genomics, and research networks, with strong attention to quality, ethics, and access across both urban and remote populations.

Industry leaders should prioritize clinically relevant panel design, rigorous validation, and scalable informatics to strengthen targeted sequencing adoption. Laboratories and solution developers need to align assay menus with current clinical guidelines, emerging biomarkers, and local disease priorities while maintaining flexibility for rapid updates. Investment in automation, sample quality control, standardized reference materials, and interoperable laboratory information systems can reduce variability and support reproducible results. Bioinformatics strategies should emphasize transparent pipelines, robust variant annotation, evidence traceability, cybersecurity, and compatibility with electronic health records. Organizations should also build multidisciplinary interpretation models that connect molecular pathologists, genetic counselors, clinicians, bioinformaticians, and data governance teams. For global implementation, leaders should adapt workflows to regional regulatory requirements, reimbursement evidence expectations, ancestry-specific variant interpretation, and local laboratory capacity. Partnerships with hospitals, public health agencies, academic networks, and biobanks can improve clinical evidence generation and expand access. Finally, responsible AI adoption should be supported by continuous validation, bias monitoring, audit trails, and clear human oversight to ensure that targeted sequencing remains accurate, explainable, and clinically useful.

This executive summary is developed through a structured secondary research approach focused on verified scientific, clinical, regulatory, and public health sources relevant to targeted sequencing. The methodology emphasizes peer-reviewed literature, clinical practice guidelines, regulatory publications, public health genomics resources, laboratory quality standards, and official healthcare policy documentation. Insights are synthesized across technology trends, clinical applications, workflow requirements, regional adoption factors, and governance considerations without using market sizing, market share, or forecasting. The analysis considers targeted sequencing across major use cases including oncology, inherited disease, reproductive health, infectious disease surveillance, pharmacogenomics, and translational research. Regional, group, and country insights are interpreted through the lens of healthcare infrastructure, genomics policy, laboratory maturity, regulatory environment, access considerations, and public health priorities. To maintain reliability, findings are framed qualitatively and based on converging evidence from recognized scientific and institutional sources rather than speculative commercial estimates.

Targeted sequencing is positioned as a high-impact genomics technology because it delivers focused, high-depth, and interpretable molecular insights for clinical care, research, and public health. Its value is strongest where actionable genes, biomarkers, or pathogen targets are well defined and where fast, reliable interpretation is essential. The next phase of progress will be defined by validated AI-enabled analytics, adaptable panel content, stronger regulatory alignment, improved reimbursement evidence, ancestry-inclusive variant databases, and wider access to quality-assured testing. Regional adoption will continue to vary according to infrastructure, policy, workforce capacity, and healthcare priorities, but the overall direction is clear: targeted sequencing is becoming an essential component of precision medicine and molecular surveillance. Organizations that combine scientific rigor, operational scalability, ethical data governance, and clinically meaningful reporting will be best positioned to translate targeted sequencing into measurable improvements in diagnosis, treatment selection, and population health.